Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 331
1.
Plast Reconstr Surg ; 148(6): 915e-927e, 2021 Dec 01.
Article En | MEDLINE | ID: mdl-34847111

BACKGROUND: Fractional carbon dioxide or erbium:yttrium-aluminum-garnet (YAG) laser combined with platelet-rich plasma has been used for postacne scars. Nevertheless, there is limited evidence on its use because of the small size of relevant studies. This study aims to evaluate the efficacy of platelet-rich plasma-assisted laser for postacne scars. METHODS: Randomized controlled trials comparing carbon dioxide or erbium:YAG laser combined with platelet-rich plasma to laser alone were searched for using the PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar databases. RESULTS: In total, 13 studies involving 672 cases were included. The overall degree of clinical improvement favored platelet-rich plasma combined with carbon dioxide laser (mean difference, 0.55; 95 percent CI, 0.40 to 0.70) or erbium:YAG laser (mean difference, 0.63; 95 percent CI, 0.31 to 0.96). Notably, the use of carbon dioxide laser combined with platelet-rich plasma was more effective in both greater than 50 percent improvement of acne scars (OR, 1.63; 95 percent CI, 1.10 to 2.42) and greater than 75 percent improvement of acne scars (OR, 2.78; 95 percent CI, 1.75 to 4.42), compared with laser alone. Erbium:YAG laser combined with platelet-rich plasma was more effective in greater than 75 percent improvement of acne scars compared with laser alone (OR, 3.45; 95 percent CI, 1.31 to 9.05). Moreover, patient satisfaction was significantly higher with platelet-rich plasma combined with carbon dioxide laser (OR, 2.98; 95 percent CI, 1.72 to 5.16) or erbium:YAG laser (OR, 2.88; 95 percent CI, 1.33 to 6.21) compared to laser alone. CONCLUSION: This meta-analysis provides reliable evidence that fractional carbon dioxide or erbium:YAG laser combined with platelet-rich plasma is an effective and safe combination therapy for postacne scars. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.


Acne Vulgaris/complications , Cicatrix/therapy , Lasers, Gas/therapeutic use , Lasers, Solid-State/therapeutic use , Platelet-Rich Plasma , Acne Vulgaris/therapy , Cicatrix/diagnosis , Cicatrix/etiology , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Dose Fractionation, Radiation , Humans , Injections, Intradermal , Patient Satisfaction , Randomized Controlled Trials as Topic , Severity of Illness Index , Treatment Outcome
2.
Eur Rev Med Pharmacol Sci ; 25(13): 4527-4534, 2021 Jul.
Article En | MEDLINE | ID: mdl-34286495

OBJECTIVE: Aim of the study was to evaluate efficacy and efficiency of 180-watt Green-Light XPS (GL-XPS) laser photoselective vaporization of the prostate (PVP) in patients under 5-Alpha-Reductase Inhibitors (5ARI) treatment. PATIENTS AND METHODS: A consecutive series of patients with lower urinary tract symptoms due to benign prostatic enlargement treated by PVP with the GL-XPS were enrolled. Patients were divided in two groups according to the chronic use (>6 months) of 5ARI. These two groups were compared on lasing density (kilojoules per prostate volume), vaporization efficiency (prostate volume per lasing time), vaporization power (kilojoules per lasing time), Prostate Specific Antigen (PSA) reduction from baseline, symptom score change from baseline and uroflowmetry parameters improvement. Follow-up was performed at 3, 6 and 12 months with International Prostate Symptom Score, Uroflowmetry parameters and PSA. RESULTS: Overall 193 patients were enrolled. Out of them 87/193 (45%) were on 5ARI treatment. No significant differences were recorded between the two groups at baseline. Median age was 68 years old and median prostate volume was 60 ml. In terms of laser efficiency, no statistically significant differences were recorded in terms of lasing time (25 min vs. 24.5 min; p>0.05); energy used (250 kJ vs. 221 kJ; p>0.05), lasing density (6.8 kJ/ml vs. 6.6 kJ/ml, p>0.05), vaporization efficiency (1.4 ml/min vs. 1.3 ml/min, p>0.05) and vaporization power (9.6 kJ/min vs. 9.4 kJ/min; p>0.05). Finally, no significant differences were also recorded postoperatively in the two groups in terms of PSA reduction, improvement in symptom score and uroflowmetry parameters (p>0.05). CONCLUSIONS: Thirty-seven efficacy and efficiency outcomes were not statistically different between the two groups. 5ARI does not reduce the performance and ability of the 180-watt Green-Light XPS laser system.


5-alpha Reductase Inhibitors/administration & dosage , Laser Therapy/instrumentation , Prostate/pathology , Prostatectomy/instrumentation , Prostatic Hyperplasia/therapy , Aged , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Follow-Up Studies , Humans , Laser Therapy/adverse effects , Male , Middle Aged , Organ Size/drug effects , Organ Size/radiation effects , Prostate/drug effects , Prostate/radiation effects , Prostatectomy/adverse effects , Prostatectomy/methods , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/pathology , Treatment Outcome
3.
Dermatol Surg ; 47(8): 1059-1064, 2021 08 01.
Article En | MEDLINE | ID: mdl-34115683

BACKGROUND: Radiofrequency (RF) and high-intensity focused electromagnetic (HIFEM) technologies are used for noninvasive body shaping as standalone modalities. OBJECTIVE: To examine the effects of novel synchronized RF and HIFEM on subcutaneous adipose tissue in a porcine animal model. MATERIALS AND METHODS: Seven large white pigs aged 6 months received 3 abdominal treatments of simultaneous application of synchronized RF and HIFEM (30 minutes, once per week). Punch biopsies of treated and control subcutaneous tissue were collected at the baseline, 4 days, 2 weeks, 1 month, and 2 months. Specimens were examined by light and scanning electron microscopy. Adipocyte volume was analyzed. Fat tissue temperature was measured in situ (fiber optic probes) and superficially (thermal imager). RESULTS: Fat layer was heated to temperatures of 42 to 45°C. Signs of fat apoptosis (shape alternations and pyknotic nuclei) appeared at day 4 and peaked between 2 weeks and 1 month. Adipocyte volume decreased significantly (p < .001) by 31.1% at 2 weeks, 1 month (-23.6%), and 2 months (-22.0%). Control samples showed healthy adipocytes. Scanning electron microscopy micrographs corroborated histology findings, showing flattened, volume-depleted and disrupted adipocytes. CONCLUSION: Synchronized RF with HIFEM procedure resulted in a significant and sustained fat reduction with no adverse events.


Body Contouring/methods , Magnetic Field Therapy/methods , Radiofrequency Therapy/methods , Subcutaneous Fat/radiation effects , Adipocytes/radiation effects , Adipocytes/ultrastructure , Animals , Body Contouring/adverse effects , Body Contouring/instrumentation , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Female , Hot Temperature/adverse effects , Magnetic Field Therapy/adverse effects , Magnetic Field Therapy/instrumentation , Microscopy, Electron , Models, Animal , Radiofrequency Therapy/adverse effects , Radiofrequency Therapy/instrumentation , Subcutaneous Fat/cytology , Subcutaneous Fat/ultrastructure , Swine
4.
Eur J Vasc Endovasc Surg ; 61(5): 820-828, 2021 05.
Article En | MEDLINE | ID: mdl-33648846

OBJECTIVE: The aim was to evaluate the short term safety and effectiveness of the Penumbra/Indigo aspiration thrombectomy Systems (Penumbra Inc.) in patients with acute lower limb ischaemia. (ALLI). Recently, endovascular vacuum assisted thrombectomy devices, similar to those used in the management of acute ischaemic stroke, have become available for peripheral arteries, but data are still scarce. METHODS: To assess vessel patency, a modified Thrombolysis in Myocardial Infarction (TIMI) classification, called TIPI (Thrombo-aspiration In Peripheral Ischaemia), is proposed. The TIPI flow is assessed at presentation, immediately after treatment with the study device, and after all adjuvant procedures. The primary outcome is the technical success of the thrombo-aspiration with the investigative system, defined as near complete or complete revascularisation TIPI 2 - 3. Safety and clinical success rate were collected at one month. RESULTS: One hundred and fifty patients were enrolled. The mean age was 72.4 years and 73.3% were male. Rutherford grade on enrolment was I in 16%, IIa in 40.7%, and IIb in 43.3% with a mean ankle brachial index of 0.19. Primary technical success (TIPI 2 - 3 flow) was achieved in 88.7% of patients. Adjunctive procedures included angioplasty/stenting of chronic atherosclerotic lesions (n = 39), thrombolysis (n = 31), covered stenting (n = 15), and supplementary Fogarty embolectomy (n = 6). After all interventions, assisted primary technical success was 95.3% (TIPI 2 - 3 in 143/150). No systemic bleeding complications or device related serious adverse events were reported. At one month follow up, one death, and one below the knee amputation were recorded. Primary patency was 92% (138/150), and the re-intervention rate was 7.33%, resulting in an assisted primary and secondary patency of 94% and 99.33%, respectively. CONCLUSION: Results from the INDIAN registry reveal that mechanical thrombectomy using the Indigo system is safe and effective for revascularisation of ALLI as a primary therapy.


Ischemia/surgery , Lower Extremity/blood supply , Peripheral Arterial Disease/surgery , Postoperative Complications/epidemiology , Thrombectomy/adverse effects , Aged , Aged, 80 and over , Amputation, Surgical/statistics & numerical data , Angioplasty/adverse effects , Angioplasty/instrumentation , Angioplasty/methods , Ankle Brachial Index , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Embolectomy/adverse effects , Embolectomy/instrumentation , Embolectomy/methods , Female , Follow-Up Studies , Humans , Ischemia/diagnosis , Ischemia/etiology , Ischemia/mortality , Lower Extremity/surgery , Male , Middle Aged , Peripheral Arterial Disease/complications , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/mortality , Postoperative Complications/etiology , Prospective Studies , Reoperation/statistics & numerical data , Stents/adverse effects , Thrombectomy/instrumentation , Thrombectomy/methods , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/methods , Treatment Outcome , Vascular Patency
5.
Am J Clin Dermatol ; 22(3): 379-394, 2021 May.
Article En | MEDLINE | ID: mdl-33432476

Warts are regularly treated by dermatologists, and while many respond readily to first-line treatments, others may represent a therapeutic challenge. Large, deep, numerous, and extensive warts; treatment-resistant lesions with higher risk for side effects, such as hypopigmentation; or patients unable to tolerate or comply with our treatment regimen, may need alternative treatment options. In this work we review the characteristics of select modalities that should be considered for difficult-to-treat warts. We discuss efficacy and tolerability data as well as practical features that can guide us to select the best treatment for every scenario. Novel approaches, still in an investigational phase, are also discussed to illustrate potential future directions of wart treatment.


Warts/therapy , Administration, Cutaneous , Antiviral Agents/administration & dosage , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Cryosurgery , Humans , Immunologic Factors/administration & dosage , Immunotherapy/methods , Injections, Intralesional , Keratolytic Agents/administration & dosage , Measles-Mumps-Rubella Vaccine/administration & dosage , Nitric Oxide/administration & dosage , Papillomavirus Vaccines/administration & dosage , Photochemotherapy/instrumentation , Photochemotherapy/methods , Salicylic Acid/administration & dosage , Treatment Outcome , Warts/immunology
7.
Arch Dermatol Res ; 313(6): 461-471, 2021 Aug.
Article En | MEDLINE | ID: mdl-32785837

The objective of this meta-analysis was performed to compare the effects of tacrolimus plus phototherapy in the treatment of patients with vitiligo. Relevant studies were identified by searching PubMed, Embase, and Web of Science databases. The main outcomes of interest included excellent response (≥ 75% repigmentation), good response (50-75% repigmentation), moderate response (25%-50% repigmentation), and poor response (< 25% repigmentation). Risk ratio (RR) with 95% confidence intervals (95% CIs) was used to calculate the data. Eleven studies were included in this study. Compared with phototherapy alone, combination treatment of tacrolimus and phototherapy significantly improved excellent response rate (RR = 1.40, 95% CI 1.16, 1.69; P < 0.001) and reduced the poor response rate (RR = 0.37, 95% CI 0.22, 0.61; P = 0.001). However, the good response rate (RR = 1.00, 95% CI 0.59, 1.69, P = 1.000) and moderate response rate (RR = 0.91, 95% CI 0.60, 1.38; P = 0.653) were not significantly different between the two treatments. Subgroup analysis suggested that combination treatment had a higher excellent response rate than phototherapy alone for lesions located in the face and proximal limbs. Both NB-UVB and EL, when added to tacrolimus, resulted in a significantly higher excellent response rate than they were used alone. Meta-regression analysis showed that age was a predictive factor that influenced the effect of combination treatment on an excellent response, in which children had a high excellent response to the treatment. Other demographic and clinical variables, including gender, disease duration, family history, and type of vitiligo, did not have any impact on the treatment effect. Combination treatment with tacrolimus and phototherapy was more effective than phototherapy monotherapy for patients with vitiligo, especially in the lesions located in the face and proximal limbs. More large-scale, well-performed trials are needed to verify our findings.


Immunosuppressive Agents/administration & dosage , Lasers, Excimer/therapeutic use , Phototherapy/methods , Tacrolimus/administration & dosage , Vitiligo/therapy , Administration, Cutaneous , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Humans , Phototherapy/instrumentation , Severity of Illness Index , Treatment Outcome , Vitiligo/diagnosis , Vitiligo/immunology
8.
Arch Dermatol Res ; 313(8): 695-704, 2021 Oct.
Article En | MEDLINE | ID: mdl-32978675

This study aimed to evaluate the effectiveness of isolated treatment with retinoic acid and its combination with the microneedling technique in facial melasma, seeking to associate these results with possible oxidative damage. This is a blinded randomized clinical trial with 42 women with facial melasma (skin phototype I-IV), randomized into Group A (microneedling and 5% retinoic acid) or Group B (5% retinoic acid alone). Four procedures were applied with 15 days intervals (4 blood collections). Clinical improvement was assessed using the Melasma Area Severity Index (MASI). Serum oxidative stress levels were evaluated by protein oxidation (carbonyl), lipid peroxidation (TBARS) and sulfhydryl groups, as well as enzyme activities of superoxide dismutase (SOD) and catalase (CAT). The statistical analyzes were performed by generalized estimation equation (GEE). There was a reduction in MASI scale and TBARS levels in both groups over time (p < 0.05), with no difference between groups (p = 0.416). There was also a substantial increase in the carbonyl levels at 30 days (p = 0.002). The SOD activity decreased after 30 days, regardless of group (p < 0.001), which was maintained after 60 days. In Group A, there was a reduction in sulfhydryl levels at 60 days (p < 0.001). It is important to highlight that both groups demonstrated efficacy in the clinical improvement of melasma within at least 60 days, reducing the MASI score by almost 50%. However, microneedling with retinoic acid seems to be the worst treatment because there is a reduction in the non-enzymatic antioxidant defense, which is important to protect against oxidative stress.


Dry Needling/methods , Facial Dermatoses/therapy , Keratolytic Agents/administration & dosage , Melanosis/therapy , Tretinoin/administration & dosage , Administration, Cutaneous , Adult , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Dry Needling/instrumentation , Facial Dermatoses/blood , Facial Dermatoses/diagnosis , Female , Humans , Keratolytic Agents/adverse effects , Lipid Peroxidation/drug effects , Melanosis/blood , Melanosis/diagnosis , Middle Aged , Oxidative Stress/drug effects , Patient Satisfaction , Severity of Illness Index , Treatment Outcome , Tretinoin/adverse effects
9.
Proc Natl Acad Sci U S A ; 117(50): 31603-31613, 2020 12 15.
Article En | MEDLINE | ID: mdl-33257581

We report on in vitro wound-healing and cell-growth studies under the influence of radio-frequency (rf) cell stimuli. These stimuli are supplied either by piezoactive surface acoustic waves (SAWs) or by microelectrode-generated electric fields, both at frequencies around 100 MHz. Employing live-cell imaging, we studied the time- and power-dependent healing of artificial wounds on a piezoelectric chip for different cell lines. If the cell stimulation is mediated by piezomechanical SAWs, we observe a pronounced, significant maximum of the cell-growth rate at a specific SAW amplitude, resulting in an increase of the wound-healing speed of up to 135 ± 85% as compared to an internal reference. In contrast, cells being stimulated only by electrical fields of the same magnitude as the ones exposed to SAWs exhibit no significant effect. In this study, we investigate this effect for different wavelengths, amplitude modulation of the applied electrical rf signal, and different wave modes. Furthermore, to obtain insight into the biological response to the stimulus, we also determined both the cell-proliferation rate and the cellular stress levels. While the proliferation rate is significantly increased for a wide power range, cell stress remains low and within the normal range. Our findings demonstrate that SAW-based vibrational cell stimulation bears the potential for an alternative method to conventional ultrasound treatment, overcoming some of its limitations.


Acoustic Stimulation/methods , Sound/adverse effects , Vibration/therapeutic use , Wound Healing/radiation effects , Acoustic Stimulation/adverse effects , Acoustic Stimulation/instrumentation , Animals , Cell Line , Cell Line, Tumor , Cell Movement/radiation effects , Cell Proliferation/radiation effects , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Dogs , Electrodes , Humans , Madin Darby Canine Kidney Cells , Oxidative Stress/drug effects , Reactive Oxygen Species
10.
J Drugs Dermatol ; 19(11): 1044-1048, 2020 Nov 01.
Article En | MEDLINE | ID: mdl-33196737

BACKGROUND: Laser resurfacing is the gold standard procedure for photodamage, but is not without downtime and risk. Use of periprocedural products containing stem cell conditioned media may improve results and optimize healing. STUDY DESIGN: This was a prospective, randomized controlled, double-blind study, evaluating the efficacy and tolerability of red deer umbilical cord-derived stem cell conditioned media (USCCM) cream and serum pre- and post- ablative facial resurfacing. METHODS AND MATERIALS: Twenty patients with moderate to severe photodamage were randomized to receive vehicle or USCCM cream and serum pre- and post- ablative resurfacing of the face. Blinded investigators rated healing, tolerability, and efficacy, while subjects rated post-procedure symptoms, tolerability, and satisfaction. RESULTS: Both the active and vehicle pre-procedure cream were soothing, calming and easy to use by all patients. There was a trend towards decreased facial erythema and crusting in the active versus vehicle group. A greater improvement in wrinkling occurred in the active group. The majority of subjects were very satisfied with the active products. There were no serious adverse events. CONCLUSION: Red deer umbilical cord-derived stem cell conditioned media (USCCM) is well tolerated, safe and efficacious for use pre- and post- facial laser resurfacing.J Drugs Dermatol. 2020;19(11): 1044-1048 doi:10.36849/JDD.2020.5246.


Cosmetic Techniques/adverse effects , Culture Media, Conditioned/adverse effects , Laser Therapy/methods , Skin Aging , Stem Cells/metabolism , Adult , Aged , Animals , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Deer , Double-Blind Method , Face , Female , Humans , Laser Therapy/adverse effects , Laser Therapy/instrumentation , Lasers, Gas/adverse effects , Male , Middle Aged , Patient Satisfaction , Rejuvenation , Skin Cream/administration & dosage , Skin Cream/adverse effects , Treatment Outcome , Umbilical Cord/cytology
11.
J Drugs Dermatol ; 19(11): 1076-1079, 2020 Nov 01.
Article En | MEDLINE | ID: mdl-33196757

BACKGROUND: Device-based therapeutic approaches have been developed to treat women’s genitourinary post-menopausal symptoms. Fractional carbon dioxide laser resurfacing (FxCO2) has been demonstrated to be safe and effective in the treatment of GSM symptoms, however the results begin to wane by 12-months post-treatment. OBJECTIVE: This study aims at assessing the application of an at-home transvaginal red and infrared light device as a maintenance treatment commencing 12 months following FxCO2 laser treatment for genitourinary syndrome of menopause (GSM). STUDY DESIGN: Subjects completing 12-month follow-up after three fractional CO2 laser vulvovaginal treatments received an at-home device and monitored for GSM symptoms with long-term follow-up to 12 months (2 years post-laser). METHODS: 10 post-menopausal subjects completing 12-months follow-up after three FxCO2 vulvovaginal treatments for GSM were treated with an at-home red and infrared LED device. Treatment consisted of intravaginal application three times per week, and subjects were followed to 1, 3, 6, and 12 months. Subjects completed the vaginal assessment scale subject satisfaction, and QUID to assess for vulvovaginal and stress urinary incontinence (SUI) symptoms. RESULTS: Vulvovaginal symptoms measured by VAS were mean 89% improved at 12-month follow-up after FxCO2 and maintained at 73% improved over baseline (2 years post-laser) following an additional 12 months of at-home transvaginal light therapy (P<0.05). VAS symptoms gradually increased over the 12 months maintenance period by a mean of 17% (P<0.05). Mean subject satisfaction was 0 at baseline, 1.86 at 1 year following FxCO2, and 1.00 after an additional 1 year of at-home light therapy. SUI symptoms as measured by QUID were mean 81% improved at 12-month follow-up after FxCO2and maintained at 38% improved over baseline (2 years post-laser) following an additional 12-months of at-home light therapy (P<0.05). SUI symptoms gradually increased by a mean of 43% over the 12-month maintenance period (P<0.05). CONCLUSIONS: At-home transvaginal red and near infrared light therapy commencing at 12 months post-FxCO2 vulvovaginal treatment in a post-menopausal population maintained statistically significant improvements in vulvovaginal and SUI symptoms over the additional12-month period (2 years post-laser); however, a gradual return of symptoms suggests that laser re-treatment or combination withhormone therapy may be necessary to maintain optimal outcomes.J Drugs Dermatol. 2020;19(11):1076-1079. doi:10.36849/JDD.2020.1012.


Female Urogenital Diseases/therapy , Lasers, Gas/therapeutic use , Phototherapy/instrumentation , Postmenopause/physiology , Self Care/instrumentation , Adult , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Female , Female Urogenital Diseases/physiopathology , Follow-Up Studies , Humans , Infrared Rays/therapeutic use , Middle Aged , Phototherapy/methods , Self Care/methods , Syndrome , Treatment Outcome , Urinary Bladder/physiopathology , Urinary Bladder/radiation effects , Vagina/physiopathology , Vagina/radiation effects , Vulva/physiopathology , Vulva/radiation effects
12.
Cochrane Database Syst Rev ; 10: CD006185, 2020 10 22.
Article En | MEDLINE | ID: mdl-33091160

BACKGROUND: Electromechanical- and robot-assisted gait-training devices are used in rehabilitation and might help to improve walking after stroke. This is an update of a Cochrane Review first published in 2007 and previously updated in 2017. OBJECTIVES: Primary • To determine whether electromechanical- and robot-assisted gait training versus normal care improves walking after stroke Secondary • To determine whether electromechanical- and robot-assisted gait training versus normal care after stroke improves walking velocity, walking capacity, acceptability, and death from all causes until the end of the intervention phase SEARCH METHODS: We searched the Cochrane Stroke Group Trials Register (last searched 6 January 2020); the Cochrane Central Register of Controlled Trials (CENTRAL; 2020 Issue 1), in the Cochrane Library; MEDLINE in Ovid (1950 to 6 January 2020); Embase (1980 to 6 January 2020); the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 20 November 2019); the Allied and Complementary Medicine Database (AMED; 1985 to 6 January 2020); Web of Science (1899 to 7 January 2020); SPORTDiscus (1949 to 6 January 2020); the Physiotherapy Evidence Database (PEDro; searched 7 January 2020); and the engineering databases COMPENDEX (1972 to 16 January 2020) and Inspec (1969 to 6 January 2020). We handsearched relevant conference proceedings, searched trials and research registers, checked reference lists, and contacted trial authors in an effort to identify further published, unpublished, and ongoing trials. SELECTION CRITERIA: We included all randomised controlled trials and randomised controlled cross-over trials in people over the age of 18 years diagnosed with stroke of any severity, at any stage, in any setting, evaluating electromechanical- and robot-assisted gait training versus normal care. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion, assessed methodological quality and risk of bias, and extracted data. We assessed the quality of evidence using the GRADE approach. The primary outcome was the proportion of participants walking independently at follow-up. MAIN RESULTS: We included in this review update 62 trials involving 2440 participants. Electromechanical-assisted gait training in combination with physiotherapy increased the odds of participants becoming independent in walking (odds ratio (random effects) 2.01, 95% confidence interval (CI) 1.51 to 2.69; 38 studies, 1567 participants; P < 0.00001; I² = 0%; high-quality evidence) and increased mean walking velocity (mean difference (MD) 0.06 m/s, 95% CI 0.02 to 0.10; 42 studies, 1600 participants; P = 0.004; I² = 60%; low-quality evidence) but did not improve mean walking capacity (MD 10.9 metres walked in 6 minutes, 95% CI -5.7 to 27.4; 24 studies, 983 participants; P = 0.2; I² = 42%; moderate-quality evidence). Electromechanical-assisted gait training did not increase the risk of loss to the study during intervention nor the risk of death from all causes. Results must be interpreted with caution because (1) some trials investigated people who were independent in walking at the start of the study, (2) we found variation between trials with respect to devices used and duration and frequency of treatment, and (3) some trials included devices with functional electrical stimulation. Post hoc analysis showed that people who are non-ambulatory at the start of the intervention may benefit but ambulatory people may not benefit from this type of training. Post hoc analysis showed no differences between the types of devices used in studies regarding ability to walk but revealed differences between devices in terms of walking velocity and capacity. AUTHORS' CONCLUSIONS: People who receive electromechanical-assisted gait training in combination with physiotherapy after stroke are more likely to achieve independent walking than people who receive gait training without these devices. We concluded that eight patients need to be treated to prevent one dependency in walking. Specifically, people in the first three months after stroke and those who are not able to walk seem to benefit most from this type of intervention. The role of the type of device is still not clear. Further research should consist of large definitive pragmatic phase 3 trials undertaken to address specific questions about the most effective frequency and duration of electromechanical-assisted gait training, as well as how long any benefit may last. Future trials should consider time post stroke in their trial design.


Orthotic Devices , Robotics/instrumentation , Stroke Rehabilitation/methods , Walking , Aged , Bias , Cause of Death , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Confidence Intervals , Electric Stimulation Therapy , Equipment Design , Exercise Therapy/methods , Gait , Humans , Middle Aged , Odds Ratio , Randomized Controlled Trials as Topic , Stroke Rehabilitation/instrumentation , Walking Speed
13.
BMC Pregnancy Childbirth ; 20(1): 617, 2020 Oct 13.
Article En | MEDLINE | ID: mdl-33050911

BACKGROUND: There is no clear consensus on the management of caesarean scar pregnancy (CSP), a complex and life-threatening condition. The objective of this study was to present a novel approach to management of CSP that combines medical therapy of multidose methotrexate and mifepristone with active surgical management by uterine curettage and consecutive local haemostasis. CASE PRESENTATION: We report on a prospective case series of six women with first trimester pregnancy, in whom the diagnosis of CSP was confirmed by 2D and color Doppler transvaginal ultrasound and serial hormone chorionic gonadotropin (hCG) testing. Women were between 23 and 36 years old and had at least one previous delivery by caesarean. At admission, gestational age ranged between 6 to 14 weeks, and serum hCG levels between 397 and 23,000 mUI/ml. Upon decision of pregnancy termination, medical management was undertaken in all cases and 1 mg/kg systemic Methotrexate was administered between 1 and 5 daily doses. Mifepristone was part of the treatment in cases with live pregnancy. Surgical management was employed for the cases were an embryo was seen by ultrasound, being prompted by inadequate response to Methotrexate and/or signs of miscarriage with vaginal bleeding. Curettage combined with local isthmic balloon or vaginal pack tamponade prevented further complications. High treatment rates with preservation of fertility was achieved in all patients except one who underwent hysterectomy for invasive placentation. Ultrasound and hCG levels surveillance ensured that the resolution of pregnancy was achieved. CONCLUSION: Women with history of delivery by caesarean section should be carefully monitored in future pregnancies for prompt diagnosis of CSP. Early diagnosis of CSP allows selection of successful conservative therapy. Through this case series we contribute with our experience to the body of knowledge about the management of this serious complication of early pregnancy.


Abortion, Induced/methods , Cesarean Section/adverse effects , Cicatrix/complications , Pregnancy Complications/therapy , Uterus/pathology , Abortion, Induced/instrumentation , Adult , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Curettage/methods , Female , Fertility Preservation/instrumentation , Fertility Preservation/methods , Humans , Methotrexate/administration & dosage , Mifepristone/administration & dosage , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/etiology , Pregnancy Trimester, First , Prospective Studies , Treatment Outcome , Ultrasonography, Doppler, Color , Uterine Artery Embolization/instrumentation , Uterine Artery Embolization/methods , Uterine Hemorrhage/etiology , Uterine Hemorrhage/prevention & control , Uterus/diagnostic imaging , Uterus/drug effects , Uterus/surgery , Young Adult
14.
Clin Transl Gastroenterol ; 11(9): e00234, 2020 09.
Article En | MEDLINE | ID: mdl-33094961

INTRODUCTION: Endoscopic bariatric and metabolic therapies can potentially reproduce similar gastric and small intestinal anatomic and physiologic manipulations as Roux-en-Y gastric bypass. This proof of concept animal study was aimed to assess the feasibility, safety, efficacy, and impact on gastrointestinal physiology of combined intragastric balloons (IGB) and duodenal-jejunal bypass liner (DJBL) for the treatment of obesity. METHODS: Five Ossabaw pigs were fed a high-calorie diet to develop obesity and were randomly assigned to receive IGB or DJBL in sequence. The weight gain rate was calculated. Fasting and postprandial blood samples were drawn before any intervention (serving as the baseline group) and 1 month after second device insertion (serving as the combination group) to measure gut neurohormonal changes and metabolic parameters. RESULTS: Four pigs successfully received a sequential device insertion. One pig developed duodenal sleeve prolapse that was spontaneously resolved. One pig was early terminated because of developing a central line infection. The rate of weight gain in the combination group (0.63 ± 1.3 kg/wk) was significantly lower than the baseline group (1.96 ± 2.17 kg/wk) and numerically lower than after insertion of the IGB (1.00 ± 1.40 kg/wk) or the DJBL (0.75 ± 2.27 kg/wk) alone. A trend of higher postprandial glucagon-like peptide-1 was observed in the combination group compared with the baseline group. DISCUSSION: A combination of IGB and DJBL is feasible and well tolerated. A strategy of sequential use of these devices might offer a synergistic approach that can enhance weight loss and metabolic outcomes.


Bariatric Surgery/instrumentation , Duodenum/surgery , Gastric Balloon , Jejunum/surgery , Obesity, Morbid/surgery , Anastomosis, Roux-en-Y/instrumentation , Anastomosis, Roux-en-Y/methods , Animals , Bariatric Surgery/methods , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Diet, Atherogenic/adverse effects , Diet, High-Fat/adverse effects , Disease Models, Animal , Feasibility Studies , Glucagon-Like Peptide 1/blood , Glucagon-Like Peptide 1/metabolism , Obesity, Morbid/blood , Obesity, Morbid/etiology , Obesity, Morbid/metabolism , Postprandial Period , Proof of Concept Study , Swine , Swine, Miniature , Weight Loss
15.
Dermatol Surg ; 46(12): 1636-1641, 2020 12.
Article En | MEDLINE | ID: mdl-32897944

BACKGROUND: Melasma is an acquired disorder of hyperpigmentation that is often recalcitrant to current therapies. Microneedling is used to treat scars, striae, and rhytides and has a relatively low risk of post-treatment dyspigmentation. Several studies have examined its use in melasma. OBJECTIVE: To review the published evidence on the efficacy and safety of microneedling in the treatment of melasma. METHODS: A systematic review was performed. A meta-analysis could not be performed because of methodological differences across studies and data heterogeneity. RESULTS: Eight studies were included for analysis. Most studies assessed the utility of microneedling in combination with other topical therapies and detected some success. However, microneedling-mediated transdermal delivery of medications is not superior to microinjections of medications. There is less evidence supporting the use of microneedling as monotherapy. Microneedling, when used with a 1064-nm Q-switched Nd:YAG laser, may provide additional benefit, although with a risk of post-treatment dyspigmentation. CONCLUSION: Based on low-quality evidence, microneedling may play a role in the treatment of melasma, with the mechanism of action likely being the facilitation of delivery of topical therapies to the epidermis and dermis, and one ancillary benefit of this approach being the very low risk of postinflammatory hyperpigmentation.


Dermatologic Agents/administration & dosage , Dry Needling/methods , Melanosis/therapy , Administration, Cutaneous , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Dermatologic Agents/adverse effects , Dry Needling/adverse effects , Dry Needling/instrumentation , Humans , Microinjections/adverse effects , Microinjections/methods , Needles/adverse effects , Transdermal Patch/adverse effects , Treatment Outcome
16.
J Surg Res ; 256: 433-438, 2020 12.
Article En | MEDLINE | ID: mdl-32795706

BACKGROUND: Severe congenital chylothorax (SCC) may result in respiratory failure, malnutrition, immunodeficiency, and sepsis. Although typically managed with bowel rest, parenteral nutrition, and octreotide, persistent chylothoraces require surgical management. At our institution, a pleurectomy, unilateral or bilateral, in combination with mechanical pleurodesis and thoracic duct ligation is performed for SCC, and we describe our approach and outcomes. MATERIALS AND METHODS: We reviewed over 15-year period neonatal patients with SCC managed surgically with pleurectomy after medical therapy was unsuccessful. Patients were divided into two groups: those who underwent pleurectomy within 28 d of diagnosis (early group) and those who underwent pleurectomy after 28 d (late group). Resolution of chylothorax was defined by the absence of clinical symptoms as well as absent or minimal pleural effusion on chest X-ray. RESULTS: Of 40 patients diagnosed with SCC over the study period, 15 underwent pleurectomy, eight early [mean time to operation = 20 (IQR 17, 23) d] and 7 late [59 (42, 75) d, P = 0.001]. Overall survival was 67% (10 of 15). Seven of 8 (88%) neonates who underwent early pleurectomy survived versus 3 of 7 (43%) who underwent late pleurectomy (P = 0.07). Length of stay was lower in the early group than the late group [73 (57, 79) versus 102 (109, 213) d, P = 0.05]. All patients who survived to discharge had resolution of their chylothorax. CONCLUSIONS: Pleurectomy with mechanical pleurodesis and thoracic duct ligation is effective in the management of severe congenital chylothorax. When performed earlier, pleurectomy for severe congenital chylothorax may be associated with improved survival and shorter hospital length of stay.


Chylothorax/congenital , Pleura/surgery , Pleurodesis/methods , Thoracic Duct/surgery , Time-to-Treatment , Chest Tubes , Chylothorax/diagnosis , Chylothorax/mortality , Chylothorax/surgery , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Female , Humans , Infant, Newborn , Infant, Premature , Length of Stay/statistics & numerical data , Ligation , Male , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome
17.
Sci Rep ; 10(1): 11380, 2020 07 09.
Article En | MEDLINE | ID: mdl-32647291

Theranostics based on two-photon excitation of therapeutics in the NIR region is an emerging and powerful tool in cancer therapy since this radiation deeply penetrates healthy biological tissues and produces selective cell death. Aggregates of gold nanoparticles coated with glutathione corona functionalized with the dansyl chromophore (a-DG-AuNPs) were synthesized and found efficient nanodevice for applications in photothermal therapy (PTT). Actually the nanoparticle aggregation enhances the quenching of radiative excitation and the consequent conversion into heat. The a-DG-AuNPs are readily internalized in Hep G2 where the chromophore acts as both antenna and transducer of the NIR radiation under two-photons excitation, determining efficient cell ablation via photothermal effect.


Low-Level Light Therapy/methods , Metal Nanoparticles/administration & dosage , Neoplasms/therapy , Photothermal Therapy/methods , Theranostic Nanomedicine/methods , Animals , Cell Line, Tumor , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Fluorescence , Glutathione/chemistry , Gold/chemistry , Humans , Infrared Rays/therapeutic use , Lasers , Low-Level Light Therapy/instrumentation , Metal Nanoparticles/chemistry , Mice , Neoplasms/pathology , Phosphatidylcholines/chemistry , Photons/therapeutic use , Photothermal Therapy/instrumentation , Theranostic Nanomedicine/instrumentation
18.
Biosci Rep ; 40(5)2020 05 29.
Article En | MEDLINE | ID: mdl-32426815

Laryngeal papillomatosis is a benign disease in the larynx but with the potential to develop into significant complications as a result of its high recurrence rate. CO2 laser and radiofrequency controlled ablation (coblation) have been used to treat recurrent respiratory papillomatosis, but detailed comparisons of their respective treatment outcomes are not fully investigated. This retrospective study examines the procedure time, time interval between interventions, blood loss during operation, post-operative complications and pain scores among patients who received either CO2 laser or radiofrequency coblation interventions for laryngotracheal recurrent respiratory papillomatosis. Compared with CO2 laser intervention, radiofrequency coblation significantly reduced operation time, time interval between interventions, blood loss during operation and number of times bipolar electrocoagulation needed in each procedure. Post-operatively, pain scores after radiofrequency coblation were significantly lower than those after CO2 laser intervention. Incidence rates of post-operative complications, in terms of palate pharyngeal mucosa damage, bleeding and subcutaneous emphysema, were also significantly reduced after radiofrequency coblation. Low-temperature radiofrequency coblation is a superior intervention compared with CO2 laser against laryngotracheal recurrent respiratory papillomatosis.


Lasers, Gas/adverse effects , Pain, Postoperative/diagnosis , Papillomavirus Infections/surgery , Radiofrequency Ablation/adverse effects , Respiratory Tract Infections/surgery , Adult , Blood Loss, Surgical/statistics & numerical data , Cold Temperature , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Female , Humans , Male , Operative Time , Pain Measurement/statistics & numerical data , Pain, Postoperative/etiology , Radiofrequency Ablation/instrumentation , Radiofrequency Ablation/methods , Retreatment/statistics & numerical data , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome
19.
J Cosmet Dermatol ; 19(5): 1086-1092, 2020 May.
Article En | MEDLINE | ID: mdl-32233007

BACKGROUND: Postacne scars have significant psychosocial distress among patients. Subcision is a well-known treatment modality specially for rolling type of acne scars, but is a crude mechanical process, which carries a risk of hematoma formation. AIMS: To compare the efficacy and safety of radiofrequency-assisted subcision (rSubcision) with conventional subcision in postacne scars. METHODS: In this randomized, split-face study, adult patients with postacne scars were randomized to receive either conventional subcision or rSubcision in 2 sessions, 4 weeks apart and followed up for 2 months. Outcome was measured using Goodman and Baron score (GBS), investigator global assessment (IGA) by two blinded dermatologists, and patient global assessment (PGA). RESULTS: Seventeen out of 21 patients completed the treatment. Statistical analysis of the results was performed using SPSS 15.0 statistical software (SPSS). Patients in both the groups had significant improvement from baseline according to quantitative scoring (P = .0001), number of scars (P = .0001), IGA, and PGA. The improvement was comparable in both the groups according to GBS and IGA but better on rSubcision side in terms of PGA. Two patients developed small entry point burn during rSubcision which healed in one month and one developed persistent hematoma with conventional subcision. CONCLUSIONS: Both modalities were comparable in terms of assessment scores and investigator assessment, but patients found improvement better on rSubcision side.


Acne Vulgaris/therapy , Cicatrix/therapy , Dermatologic Surgical Procedures/methods , Electrosurgery/methods , Radiofrequency Therapy/methods , Acne Vulgaris/complications , Adult , Cicatrix/diagnosis , Cicatrix/etiology , Combined Modality Therapy/adverse effects , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Dermatologic Surgical Procedures/adverse effects , Dermatologic Surgical Procedures/instrumentation , Electrosurgery/adverse effects , Electrosurgery/instrumentation , Face , Female , Humans , Male , Radiofrequency Therapy/adverse effects , Radiofrequency Therapy/instrumentation , Severity of Illness Index , Skin/radiation effects , Treatment Outcome
20.
Med Sci Monit ; 26: e919962, 2020 Mar 11.
Article En | MEDLINE | ID: mdl-32158013

BACKGROUND The aim of this study was to define whether the addition of thoracic lavage to chest drainage was more efficient than the use of chest drainage alone in the treatment for anastomotic leaks in type III esophageal atresia. MATERIAL AND METHODS The clinical data of 42 patients with anastomotic leakage treated with the addition of thoracic lavage from January 2012 to March 2019 in our hospital were analyzed retrospectively. The clinical data of 50 patients with anastomotic leakage treated without thoracic lavage from March 1999 to December 2011 in our hospital were selected as controls. RESULTS The duration of fistula healing, mechanical ventilation, hospitalization in intensive care unit, and gastric tube intubation in the thoracic lavage group were significantly shorter than those in the non-lavage group. The cost of hospitalization and the incidence of severe pneumonia were significantly lower in the thoracic lavage group than in the non-lavage group. The diameter of the anastomotic opening after anastomotic fistula healing was wider in the thoracic lavage group than in the non-lavage group. CONCLUSIONS The technique of thoracic lavage is simple, economical and convenient and can effectively promote the healing of anastomotic fistulas, accelerate postoperative recovery in children and reduce the cost of treatment.


Anastomotic Leak/therapy , Drainage/methods , Esophageal Atresia/surgery , Esophagectomy/adverse effects , Therapeutic Irrigation/methods , Anastomosis, Surgical/adverse effects , Anastomotic Leak/etiology , Chest Tubes , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Drainage/instrumentation , Esophagectomy/methods , Feasibility Studies , Female , Humans , Infant, Newborn , Male , Retrospective Studies , Treatment Outcome
...